ANI Pharmaceuticals posts record Q3 revenue of $148.3M, raises 2024 guidance

ANI PHARMACEUTICALS INC

2024-Q3 EPS reported -$0.49 revenue$423,802,000

Record quarterly net revenue of $148.3M (+12.5% YoY); Cortrophin Gel revenue $52.6M (+76.8%).
GAAP net loss of $24.2M (-$1.27 diluted EPS) vs net income of $9.5M year ago; adjusted non-GAAP EPS of $1.34.
Completed Alimera acquisition on Sept 16, adding ILUVIEN and YUTIQ; contributed $3.9M revenue in partial quarter.
Raised FY2024 guidance: net rev $594-602M, adjusted EBITDA $149-153M, adjusted EPS $4.90-$5.05.
New capital structure with $316.25M 2.25% convertible notes due 2029; expected to reduce interest expense ~$39M annually.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.